Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. EMTN Programme Routine Technical Update

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

EMTN Programme Routine Technical Update

11 Jun 2020 07:00

RNS Number : 6000P
AstraZeneca PLC
11 June 2020
 

11 June 2020 07:00 BST

 

EMTN Programme Routine Technical Update: Publication of Prospectus

 

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

 

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

 

The last drawdown under the EMTN programme was in 2016.

 

To view the full document, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/6000P_1-2020-6-10.pdf

 

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

http://www.morningstar.co.uk/uk/NSM

 

 

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDIFLFFARAIILII
8910111213141516
Date   Source Headline
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU
26th Jan 20213:00 pmRNSBlock listing application
26th Jan 20217:00 amRNSSymbicort approved in China for mild asthma
25th Jan 20217:05 amRNSCalquence approved in Japan for CLL
25th Jan 20217:00 amRNSCalquence met primary endpoint against ibrutinib
20th Jan 20217:00 amRNSEnhertu approved in the EU for breast cancer
18th Jan 20217:00 amRNSEnhertu approved in the US for gastric cancer
15th Jan 20217:00 amRNSImfinzi new dosing approved in EU
6th Jan 20217:00 amRNSFarxiga granted US Priority Review for CKD
4th Jan 20213:00 pmRNSTotal Voting Rights
4th Jan 20217:00 amRNSAtacand divestment in over 70 countries completed
30th Dec 20207:00 amRNSAstraZeneca’s COVID-19 vaccine authorised in UK
29th Dec 20207:00 amRNSLynparza approved in Japan for three cancers
21st Dec 20207:05 amRNSTagrisso approved in the US for early lung cancer
21st Dec 20207:00 amRNSUpdate on US regulatory review of roxadustat
17th Dec 20204:00 pmRNSDirector/PDMR Shareholding
16th Dec 20206:15 pmRNSDirector/PDMR Shareholding
15th Dec 20207:00 amRNSImfinzi new dose receives positive EU CHMP opinion
14th Dec 20207:05 amRNSTrastuzumab deruxtecan positive CHMP
14th Dec 20207:00 amRNSTrixeo Aerosphere approved in the EU for COPD
14th Dec 20207:00 amRNSAstraZeneca to acquire Alexion Pharmaceuticals Inc
1st Dec 20203:00 pmRNSBlock listing Interim Review
1st Dec 20203:00 pmRNSTotal Voting Rights
1st Dec 20207:00 amRNSCrestor to be divested to Grünenthal in Europe
30th Nov 20207:00 amRNSForxiga approved in Japan for heart failure
23rd Nov 20207:00 amRNSAZD1222 vaccine effective against COVID-19
20th Nov 20207:00 amRNSImfinzi new dosing approved in the US
10th Nov 20207:00 amRNSTezepelumab Phase III trial met primary endpoint
9th Nov 20207:00 amRNSCalquence approved in the EU for CLL
6th Nov 20207:00 amRNSBrilinta approved in the US in stroke
5th Nov 20207:15 amRNSLynparza approved in the EU for wider ovarian use
5th Nov 20207:10 amRNSLynparza approved in the EU for prostate cancer
5th Nov 20207:05 amRNSForxiga approved in the EU for heart failure
5th Nov 20207:00 amRNSAZN: Year-to-date and Q3 2020 results
2nd Nov 20203:00 pmRNSTotal Voting Rights
30th Oct 20207:00 amRNSAtacand to be divested in more than 70 countries
29th Oct 20207:00 amRNSDirectorate Change
28th Oct 20207:03 amRNSEnhertu US Priority Review in gastric cancer
28th Oct 20207:00 amRNSForxiga CV outcomes benefit approved in China
20th Oct 20207:00 amRNSTagrisso adjuvant lung cancer US Priority Review
19th Oct 20207:00 amRNSForxiga HF receives positive CHMP opinion
19th Oct 20207:00 amRNSTrixeo Aerosphere receives positive CHMP opinion
12th Oct 20207:00 amRNSCOVID-19 antibodies advance and get US funding
2nd Oct 202011:19 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSFarxiga granted US BTD in chronic kidney disease
1st Oct 20203:00 pmRNSTotal Voting Rights
25th Sep 20207:00 amRNSDirectorate Change
8910111213141516

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
DNLM
Dunelm
LSE
-0.52%
ALAI
ALAI.L
LSE
0.00%
BPM
B.p Marsh
LSE
1.59%
NFC
NFC.L
LSE
0.00%
SMS
SMS.L
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
EZJ
easyJet
LSE
0.34%